Grant Skrepnek to Cost-Benefit Analysis
This is a "connection" page, showing publications Grant Skrepnek has written about Cost-Benefit Analysis.
Connection Strength
1.012
-
Foot-in-wallet disease: tripped up by "cost-saving" reductions? Diabetes Care. 2014 Sep; 37(9):e196-7.
Score: 0.456
-
The cost-effectiveness of sertraline in the treatment of depression. Expert Opin Pharmacother. 2008 Oct; 9(14):2497-508.
Score: 0.303
-
Cost-effectiveness of urokinase and alteplase for treatment of acute peripheral artery disease: comparison in a decision analysis model. Am J Health Syst Pharm. 2008 Aug 01; 65(15):1435-42.
Score: 0.075
-
Regression methods in the empiric analysis of health care data. J Manag Care Pharm. 2005 Apr; 11(3):240-51.
Score: 0.059
-
Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy. 2005 Mar; 25(3):325-34.
Score: 0.059
-
Perspectives for managed care organizations on the burden of multiple sclerosis and the cost-benefits of disease-modifying therapies. J Manag Care Pharm. 2013 Jan-Feb; 19(1 Suppl A):S41-53.
Score: 0.025
-
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care System. Pharmacotherapy. 2007 Jun; 27(6):813-24.
Score: 0.017
-
Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Curr Med Res Opin. 2007 Feb; 23(2):251-8.
Score: 0.017